All articles tagged with #lumateperone
Johnson & Johnson's FDA approval of CAPLYTA (lumateperone) as an adjunctive treatment for major depressive disorder in adults offers a new hope for remission, demonstrating efficacy and a favorable safety profile based on Phase 3 trials, potentially transforming treatment expectations for depression.
Lumateperone, a second-generation antipsychotic, has been approved by the FDA for the treatment of schizophrenia. It has a unique mechanism of action compared to other antipsychotics in that it antagonizes the central 5HT2A receptors and postsynaptic D2 receptors. Lumateperone has been shown to have similar efficacy and adverse effect profiles as commonly used first-line, second-generation antipsychotics. It may be used as a first-line treatment for schizophrenia and may be beneficial to patients who failed other second-generation antipsychotics.